# MRD

Illumina’s Genomic Gambit: Standardizing the Search for Cancer’s Ghost Cells

Illumina has launched its first commercial whole-genome sequencing kit for Minimal Residual Disease (MRD) research, aiming to standardize high-sensitivity cancer monitoring. The solution supports both solid and liquid tumors, marking a significant shift from targeted gene panels to comprehensive genomic surveillance in clinical research.